IP Library Granted Patent US 8,133,959
Granted Patent B2
US 8,133,959 · App. 13/101,499 · Granted Mar 13, 2012

Side-chain crystallizable polymers for medical applications

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,133,959
App. No.
13/101,499
Granted
Mar 13, 2012
Kind
B2
Abstract

Inherently radiopaque side-chain crystallizable polymers (IRSCCP's) are useful in various medical applications. An example of a IRSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer, the heavy atoms being present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes a IRSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product.

Claims (26)

1. A medical device that comprises a polymeric material, wherein the polymeric material comprises:

a main chain;

a plurality of crystallizable side chains; and

a plurality of heavy atoms attached to the polymer, the heavy atoms being present in an amount that is effective to render the polymer inherently radiopaque.

2. The medical device of claim 1 in which the polymeric material comprises a second polymer in admixture with the inherently radiopaque polymer.

3. The medical device of claim 1 in which the inherently radiopaque polymer is bioresorbable.

4. The medical device of claim 1 that is configured to be deliverable to a body cavity of a mammal.

5. The medical device of claim 4 that is configured to be deliverable by injection or by catheter.

6. The medical device of claim 4 that comprises an embolotherapy product, the embolotherapy product comprising at least a portion of the inherently radiopaque polymer.

7. The medical device of claim 6 in which at least a portion of the inherently radiopaque polymer in the embolotherapy product is formed into at least one configuration selected from the group consisting of a rod, a particle, or a sheet.

8. The medical device of claim 4 in which the polymeric material has a melting point in the range of about 30° C. to about 80° C.

9. The medical device of claim 8 in which the polymeric material is configured to flow at a temperature above the melting point.

10. The medical device of claim 9 in which the polymeric material has a viscosity in the range of about 50 cP to about 500 cP at the temperature above the melting point.

11. The medical device of claim 9 in which the polymeric material has a viscosity in the range of about 500 cP to about 5,000 cP at the temperature above the melting point.

12. The medical device of claim 9 in which the polymeric material has a viscosity in the range of about 5,000 cP to about 250,000 cP at the temperature above the melting point.

13. The medical device of claim 9 in which the polymeric material has a viscosity in the range of about 250,000 cP to about 1,000,000 cP at the temperature above the melting point.

14. The medical device of claim 9 in which the polymeric material comprises a crystalline region and a non-crystalline region at a temperature below the body temperature of the mammal.

15. The medical device of claim 14 in which the non-crystalline region has a glass transition temperature that is higher than the body temperature.

16. The medical device of claim 14 in which the non-crystalline region has a glass transition temperature that is lower than the body temperature.

17. The medical device of claim 9 in which the polymeric material is configured to form a solid mass upon delivery to the body cavity, the solid mass at least partically conforming to an interior dimension of the body cavity.

18. The medical device of claim 17 in which the polymeric material comprises an excipient selected from the group consisting of a photopolymerizable material, a blood reactive substance and a nucleating agent.

19. The medical device of claim 17 in which the solid mass retains a preformed shape.

20. The medical device of claim 1 that further comprises an effective amount of at least one therapeutic agent.

21. The medical device of claim 20 in which the therapeutic agent is selected from the group consisting of a chemotherapeutic agent, a non-steroidal anti-inflammatory, a steroidal anti-inflammatory, and a wound healing agent.

22. The medical device of claim 1 that further comprises an effective amount of at least one magnetic resonance enhancing agent.

23. The medical device of claim 1 that is configured to be deliverable to a skeletal tissue.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2020
From: REVA MEDICAL, INC.
To: REVA MEDICAL, LLC
Reel/Frame 054778/0748 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Feb 27, 2020
From: GOLDMAN SACHS INTERNATIONAL, AS ADMINISTRATIVE AGENT
To: REVA MEDICAL, INC.
Reel/Frame 052045/0383 →
NOTICE OF GRANT OF SECURITY INTEREST IN U.S. PATENTS Recorded Apr 9, 2019
From: REVA MEDICAL, INC.
To: GOLDMAN SACHS INTERNATIONAL AS ADMINISTRATIVE AGENT
Reel/Frame 048834/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2011
From: BRANDOM, DONALD K.; ZELTINGER, JOAN; SCHMID, ERIC V.; MALLON, JOSEPH J.
To: REVA MEDICAL, INC.
Reel/Frame 026256/0618 →